Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
This trial is active, not recruiting.
|Start date||May 2011|
|Trial identifier||NCT01460862, HEORUS0091|
A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.
Frequency of emergency-department visits and hospitalizations
time frame: 12 months
Male or female participants at least 12 years old.
Inclusion Criteria: - ≥12 years of age with a documented Cystic fibrosis (CF) diagnosis, - on Long acting Beta antagonist- Inhaled Corticosteroid (LABA-ICS) at baseline, - uncontrolled asthma at baseline. Exclusion Criteria: Other protocol-defined inclusion/exclusion criteria may apply.
|Official title||Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations Among Patients With Uncontrolled Asthma Receiving High Dose Inhaled Corticosteroids|
Call for more information